Study design
migraine
MIGRAINE
DELIVER was a multicenter, parallel-group, randomized, double-blind, placebo-controlled phase 3b clinical trial that evaluated the efficacy and safety of eptinezumab for migraine prevention in patients for whom previous preventive treatments failed. The total study duration was 76 weeks, including a screening period of 28‒30 days, a placebo-controlled period of 24 weeks, and a dose-blinded extension period of 48 weeks. The detailed methodology has been published [